Table 9.
Fecal SCFA levels for the IBS subtypes in the placebo, 30‐g, and 60‐g groups before and after FMT
| Acid | Group | IBS‐D | p | IBS‐C | p | IBS‐M | p | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Before | After | Before | After | Before | After | |||||
| Total SCFAs | Placebo | 63.8 ± 22.2 | 66.5 ± 22.5 | .742 | 71.3 ± 25.5 | 67.6 ± 24.0 | .524 | 90.3 ± 64.0 | 75.9 ± 23.7 | .508 |
| 30‐g group | 86.3 ± 26.5 | 80.2 ± 24.8 | .388 | 66.8 ± 26.0 | 68.2 ± 25,9 | .874 | 80.3 ± 62.3 | 59.0 ± 27.4 | .306 | |
| 60‐g group | 68.0 ± 24.9 | 88.8 ± 40.3 | .016* | 59.3 ± 27.6 | 92.5 ± 54.4 | .011* | 90.6 ± 62.6 | 93.6 ± 48.6 | .811 | |
| Acetic acid | Placebo | 37.7 ± 11.0 | 42.3 ± 15.6 | .317 | 40.0 ± 16.0 | 38.4 ± 15.5 | .627 | 49.1 ± 27.1 | 38.0 ± 10.0 | .175 |
| 30‐g group | 53.0 ± 17.9 | 45.7 ± 14.7 | .141 | 34.6 ± 11.4 | 37.8 ± 14.0 | .392 | 44.9 ± 30.2 | 35.5 ± 15.4 | .352 | |
| 60‐g group | 38.0 ± 14.1 | 38.8 ± 14.7 | .846 | 38.4 ± 17.3 | 48.4 ± 29.7 | .209 | 56.4 ± 31.1 | 51.5 ± 24.7 | .478 | |
| Propionic acid | Placebo | 10.9 ± 4.7 | 10.8 ± 4.5 | .935 | 10.5 ± 5.2 | 11.6 ± 5.4 | .320 | 18.0 ± 13.1 | 12.2 ± 5.4 | .220 |
| 30‐g group | 15.8 ± 9.6 | 13.9 ± 7.1 | .502 | 11.7 ± 6.5 | 9.5 ± 5.5 | .149 | 12.4 ± 12.8 | 10.2 ± 7.3 | .645 | |
| 60‐g group | 12.5 ± 6.8 | 12.9 ± 7.8 | .740 | 13.7 ± 9.2 | 14.5 ± 11.1 | .747 | 17.9 ± 13.1 | 15.0 ± 11.9 | .303 | |
| Isobutyric acid | Placebo | 1.3 ± 1.0 | 1.3 ± 1.0 | .949 | 1.2 ± 9.5 | 1.2 ± 0.7 | .906 | 2.3 ± 2.7 | 1.5 ± 0.6 | .338 |
| 30‐g group | 1.3 ± 0.6 | 1.4 ± 0.6 | .295 | 1.5 ± 1.1 | 1.4 ± 0.6 | .623 | 1.5 ± 1.2 | 1.1 ± 0.3 | .336 | |
| 60‐g group | 1.3 ± 0.8 | 2.1 ± 1.3 | .036* | 1.2 ± 0.7 | 1.9 ± 1.6 ± | .029* | 1.2 ± 0.3 | 1.2 ± 0.6 | .855 | |
| Butyric acid | Placebo | 12.9 ± 8.1 | 11.5 ± 5.6 | .570 | 12.5 ± 8.2 | 11.9 ± 6.3 | .726 | 19.0 ± 7.9 | 14.2 ± 7.9 | .086 |
| 30‐g group | 16.2 ± 10.0 | 17.8 ± 8.3 | .558 | 8.5 ± 5.0 | 15,4 ± 11.4 | .007* | 7.3 ± 4.8 | 18.5 ± 14.6 | .023* | |
| 60‐g group | 12.5 ± 10.5 | 20.0 ± 15.9 | .035* | 13.2 ± 7.8 | 19.5 ± 14.7 | .032* | 11.4 ± 11.0 | 18.3 ± 15.2 | .025* | |
| Isovaleric acid | Placebo | 2.0 ± 1.6 | 1.7 ± 1.5 | .529 | 1.7 ± 0.8 | 1.9 ± 1.2 | .547 | 3.4 ± 4.3 | 2.1 ± 1.1 | .260 |
| 30‐g group | 1.8 ± 1.0 | 1.8 ± 1.1 | .911 | 2.3 ± 1.6 | 1.9 ± 0.9 | .437 | 2.1 ± 1.7 | 2.0 ± 0.6 | .804 | |
| 60‐g group | 1.9 ± 1.1 | 3.6 ± 2.1 | .043* | 1.8 ± 1.2 | 2.0 ± 1.2 | .731 | 3.5 ± 4.8 | 2.5 ± 1.3 | .474 | |
| Valeric acid | Placebo | 1.5 ± 1.0 | 1.3 ± 0.8 | .410 | 1.3 ± 0.6 | 1.5 ± 0.5 | .356 | 2.7 ± 2.9 | 1.7 ± 0.6 | .316 |
| 30‐g group | 1.6 ± 0.7 | 1.7 ± 0.7 | .420 | 2.4 ± 3.0 | 1.5 ± 0.8 | .207 | 1.5 ± 1.2 | 1.6 ± 0.8 | .825 | |
| 60‐g group | 1.5 ± 1.0 | 2.2 ± 1.7 | .015* | 1.6 ± 1.0 | 1.8 ± 1.2 | .429 | 2.6 ± 2.9 | 1.9 ± 1.4 | .315 | |
| Isocapronic acid | Placebo | 0.013 ± 0.034 | 0.038 ± 0.126 | .451 | 0.008 ± 040 | 0.000 ± 0.000 | .328 | 0.012 ± 0.036 | 0.000 ± 0.000 | .351 |
| 30‐g group | 0.0 ± 0.0 | 0.0 ± 0.0 | .3 | 0.0 ± 0.0 | 0.0 ± 0.0 | .3 | 0.0 ± 0.0 | 0.0 ± 0.0 | .3 | |
| 60‐g group | 0.008 ± 0.030 | 0.017 ± 0.058 | .874 | 0.020 ± 0.082 | 0.013 ± 040 | .555 | 0.0 ± 0.0 | 0.0 ± 0.001 | .351 | |
| Capronic acid | Placebo | 0.380 ± 0.694 | 0.380 ± 0.568 | >.999 | 0.510 ± 0.735 | 0.546 ± 0.834 | .900 | 0.482 ± 0.726 | 0.355 ± 0.836 | .582 |
| 30‐g group | 0.7 ± 0.9 | 0.5 ± 0.8 | .190 | 0.6 ± 1.0 | 0.5 ± 0.9 | .428 | 1.1 ± 2.0 | 0.5 ± 0.7 | .260 | |
| 60‐g group | 1.4 ± 2.6 | 1.2 ± 2.1 | .900 | 0.537 ± 0.747 |
0.640 ± 0.993 |
.434 | 0.689 ± 0.956 | 0.256 ± 0.381 | .216 | |
Data are mean ± SD values expressed in units of mmol/kg wet weight. * Statistically significant compared to baseline.